Clinical Trial

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Study acronym: PEACE2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with high-risk localized prostate cancer (with a stringent selection of patients with at least 2 high-risk features), in a 2 by 2 factorial trial.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2013-09-24; most recent amendment 2025-07-29.
Status change: Recruiting → Active, Not Recruiting 2021-10-05
Status change: Suspended → Recruiting 2020-09-22
Status change: Recruiting → Suspended 2020-04-22
Status change: Active, Not Recruiting → Recruiting 2014-01-06
Trial Details
NCT Number NCT01952223
Lead Sponsor UNICANCER
Collaborators: Sanofi
Conditions Adenocarcinoma of Prostate, Progression of Prostate Cancer
Enrollment 761 participants
Start Date 2013-12
Primary Completion 2025-12 (estimated)
Study Completion 2041-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-30